Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.71 |
| ▸ | CA5A | P35218 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine SCHEMBL14031844 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL5505924 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12232219 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL977919 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12018226 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL12019517 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL3047091 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL3655059 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL6882489 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B | |
| Fludarabine SCHEMBL13046076 | 1.00 | LMNA (1.00) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| EP-2509990-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245029-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-09-27 | — | — | US | disclosed |
| WO-2011069688-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-06-16 | — | — | WO | disclosed |
| US-7678782-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1974026-A2 | MUTANT DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGene A/S (DK) | 2008-10-01 | — | — | EP | disclosed |
| US-20070248543-A1 | Chicken Deoxycytidine and Deoxyadenosine Kinase Enzymes and Their Use | ZGENE A/S (DK) | 2007-10-25 | — | — | US | disclosed |
| WO-2007079753-A2 | MUTANT DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGENE A/S (DK) | 2007-07-19 | — | — | WO | disclosed |
| EP-1781788-A2 | CHICKEN DEOXYCYTIDINE AND DEOXYADENOSINE KINASE ENZYMES AND THEIR USE | ZGene A/S (DK) | 2007-05-09 | — | — | EP | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-6656955-B2 | Side effect reduction; synergistic mixture | N-GENE RESEARCH LABORATORIES, INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1358200-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | Xenoport, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6440998-B1 | Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative | N-GENE RESEARCH LABORATORIES, INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2002-07-25 | — | — | US | disclosed |
| WO-2002044324-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0993304-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-Gene Research Laboratories Inc. (US) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998058676-A1 | PHARMACEUTICAL COMPOSITION HAVING ENHANCED ANTITUMOR ACTIVITY AND/OR REDUCED SIDE EFFECTS, CONTAINING AN ANTITUMOR AGENT AND AN HYDROXAMIC ACID DERIVATIVE | N-GENE RESEARCH LABORATORIES INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0759926-B1 | PROCESS FOR PRODUCING ARABINO-NUCLEOSIDES | SCHERING AG (DE) | 1998-08-19 | — | — | EP | disclosed |
| US-5712099-A | Process for the production of arabinonucleosides | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-01-27 | — | — | US | disclosed |
| US-4357324-A | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1982-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | LMNA 3602/4885NT5E 1333/4885HIF1A 4760/4885 |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | LMNA 3602/4885NT5E 1333/4885HIF1A 4760/4885 |
| US-20120245029-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | TYMP, PNP, MTAP | LMNA 2238/4885NT5E 224/4885HIF1A 2229/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885NT5E 39/4885HIF1A 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.